Skip to content

Preclinical screening for dementia and cognitive decline

Cognitive decline prediction based on neuroimaging technique and its application in preclinical diagnosis and treatment of AD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021938
Enrollment
Unknown
Registered
2019-03-17
Start date
2019-03-25
Completion date
Unknown
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Function Decline, Dementia

Interventions

Sponsors

Nanchong Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. All participants are required to meet: (1) Hamilton Anxiety Scale: 19 points, secondary school > 22 points, university > 24 points; MMSE: illiterate > 17 points, Elementary school > 20 points, junior high school and above > 24 points; CDR: 0 points; (3) Each cognitive domain check is within the normal range or only one check score is decreased;FAQ 19 points, secondary school > 22 Points, university > 24 points; MMSE: illiterate > 17 points, primary school > 20 points, junior high school and above > 24 Points; CDR: 0 points; (4) With or without a slight cognitive decline (down 1SD or more) or FAQ=6-8 points; 4. Mild cognitive impairment Based on the 2011 NIA-AA Diagnostic Criteria and Jak/Bondi's 2014 Quantitative Criteria/ADNI Database Enrollment Criteria, the following are developed: (1) The chief complaint of cognitive decline, or the cognitive decline reported by the insider (2) MMSE: illiterate > 17 points, primary school > 20 points, junior high school and above > 24 points; MoCA-B: Primary school and below = 19 points, secondary school = 22 points, university = 24 points; CDR = 0.5; not reached AD dementia level; (3) Diagnose MCI (Jak/Bondi Standard) by reaching any of the following three criteria: 1) 2 indicators of the same cognitive domain are impaired (>1SD); 2) 1 test score is impaired in 3 cognitive domains (>1SD); 3) FAQ = 9; 3 cognitive domains: memory, execution, language; 4 basic tests: AVLT, TMT, AFT,BNT; 6 indicators: AVLT's free recall and recognition, STT-A, STT-B, AFT,BNT; 5. AD dementia (1) The chief complaint of memory loss, or the memory loss reported by the insider; (2) Impaired cognitive function, confirmed by MMSE, MoCA-B and CDR; (3) impaired occupation, social ability or daily living ability; (4) It is likely that the diagnostic criteria for AD are met in accordance with the NIA-AA diagnostic criteria;

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Other neurological diseases that may cause cognitive decline in addition to suspected early Alzheimer's disease: such as Parkinson's disease, vasogenic dementia, Huntington's disease, positive pressure hydrocephalus, brain tumor, progressive nucleus Upper palsy, epilepsy, subdural hematoma, multiple sclerosis or brain trauma caused by nervous system damage and other brain structural abnormalities; other systemic diseases that can cause cognitive decline: such as Hashimoto's encephalopathy, metabolic encephalopathy, Paralytic dementia, anemia, hepatic encephalopathy, renal encephalopathy, etc. (2) Clinical/baseline stage MRI can be seen in infarction, infection or other focal injury; multiple luminal infarction or luminal infarction is located in the important memory brain area; (3) There are pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the body; foreign bodies in the eyes, skin or body; (4) History of mental illness such as severe depression, two-way disorder, and schizophrenia (DSM-V diagnostic criteria); (5) A history of alcohol or substance abuse/addiction in the past two years (DSM-V diagnostic criteria); (6) The system cannot be completed until any other systemic disease or uncertainty.

Design outcomes

Primary

MeasureTime frame
SCD diagnosis based on the scales;MRI;APOE genotype;

Countries

China

Contacts

Public ContactGuoqian Xing, Ruowei Liu

97 Renmin Road South, Shunqing District, Nanchong, Sichuan, China

3031310262@qq.com+86 15908276997, +86 13990800125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026